Overview

Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate if AGI-134 given alone is safe and tolerate in treating patients with unresectable/metastatic solid tumours.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Agalimmune Ltd.
Treatments:
Pembrolizumab